Skip to main content
. 2020 Nov 11;13:605–614. doi: 10.2147/JAA.S270298

Table 3.

Reasons for Stopping Anti-IL-5Rα Therapy in 10 Patients. Multiple Answers per Patient Were Possible

Reasons for Stopping Anti-IL-5Rα Therapy n (% of All 60 Patients)
Inadequate treatment response 4 (7)
Loss of Effectiveness (long term therapy or too long intervals) 2 (3)
No effect on nasal polyps 1 (2)
Adverse effects – total 3 (5)
 Weight loss 1 (2)
 Coronary artery spasm during therapy with benralizumab and sumatriptan 1 (2)
 Recurrence of chronic urticaria 1 (2)